The setback marks the second this year for Telix’s radiodiagnostic portfolio, after the Australian developer received a complete response letter in April for a separate PET agent aimed at brain cancer ...

Plexium has raised $60.1 million, providing an infusion of cash for the r | Plexium has raised $60.1 million, providing an infusion of cash to the recently slimmed-down protein degrader specialist ...

Mere months after its cancer blockbuster hopeful topped Bayer’s Stivarga in a phase 3 trial, Exelixis is conducting a ...

Wugen has raised $115 million, tapping a Fidelity-led syndicate to fund its pursuit of FDA approval for the first ...

A new foundation from the estate of late Microsoft co-founder Paul Allen has launched with a set of four research grant ...

Oral therapy Relyvrio, which Amylyx is again referring to as AMX0035, was tested in progressive supranuclear palsy (PSP), a ...

As obesity pioneer Novo Nordisk loses ground in the race for next-generation drugs, the Danish pharma giant is betting on novel RNA technology to bolster its early-stage pipeline.  | As obesity ...

Eight months after Sanofi’s former chief medical officer, Dietmar Berger, M.D., departed, the French drugmaker has selected ...

Lineage Cell Therapeutics has found an experienced hearing loss partner to advance a potentially novel transplant for ...

Abbott has collected a green light in Europe for its dissolving, drug-laden stent in peripheral artery disease, following its ...

The National Cancer Institute (NCI) is ending its support for a 26-year-old push to advance clinical trials for children with ...

Novartis is putting down $30 million, with a potential $772 million on the line, to work with BioArctic’s tech to find a new ...